Longest HIFU Clinical Results Confirm Addition to Standard of Care Protocols; Symposium Confirms Ablatherm Strong Outcomes

Company Restarts US Trials for Localized Prostate Cancer HIFU

Company Reclaims Full US Market Rights; Ablatherm-HIFU Trial to Resume Immediately

EDAP Announces Details on Termination Agreement With HealthTronics LYON, France, April 12 /PRNewswire-FirstCall/ -- EDAP TMS S.A. (NASDAQ: EDAP), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer and the international leader in the development, production,

From UroToday.com: Ablatherm® - HIFU: A New Perspective in 2007, the Year of the First Long Term Clinical Results on the Treatment of Localised Prostate Cancer UroToday.com announced today the addition of Ablatherm® - HIFU: A New Perspective in 2007, the Year of the First Long Term Clinical Results

Duke Performs First Treatments under EDAP Study Sponsorship

EDAP TMS S.A. to Release 2007 First Quarter Results LYON, France , May 7 /PRNewswire-FirstCall/ -- EDAP TMS S.A. (Nasdaq: EDAP), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer and the international leader in the development, production, and distribution

EDAP to Accelerate Treatment Rates at Study Centers

European RPP Program on Target for 2008 Profitability; FDA Trial Launch Positions EDAP for Direct USA Control; EDAP, China Medical Alliance Unites HIFU Leaders

European Marketing and Education Strategy Validated